Next Article in Journal
Characterization of Heterotrimeric G Protein γ4 Subunit in Rice
Next Article in Special Issue
Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis
Previous Article in Journal
Risk Factors and Pathogenesis of HIV-Associated Neurocognitive Disorder: The Role of Host Genetics
Previous Article in Special Issue
Hepatocyte Growth Factor Activator: A Proteinase Linking Tissue Injury with Repair
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(11), 3595;

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
These authors contributed equally to this work.
Authors to whom correspondence should be addressed.
Received: 10 October 2018 / Revised: 9 November 2018 / Accepted: 11 November 2018 / Published: 14 November 2018
(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF))
Full-Text   |   PDF [595 KB, uploaded 14 November 2018]   |  


An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved also in the immune response, mainly modulating dendritic cells functions. In general, the pathway seems to play an immunosuppressive role, thus hypothesizing that it could constitute a mechanism of primary and acquired resistance to cancer immunotherapy. Recently, some approaches are being developed, including drug design and cell therapy to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition. This approach could represent a new weapon in cancer therapy in the future. View Full-Text
Keywords: HGF; MET; immune system; cancer; immunotherapy HGF; MET; immune system; cancer; immunotherapy

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Papaccio, F.; Della Corte, C.M.; Viscardi, G.; Di Liello, R.; Esposito, G.; Sparano, F.; Ciardiello, F.; Morgillo, F. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. Int. J. Mol. Sci. 2018, 19, 3595.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top